The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
99
Tablets, Oral, Once daily, 12 weeks
Tablets, Oral, Once daily, 12 weeks
Local Institution
Kogarah, New South Wales, Australia
Local Institution
Greenslopes, Queensland, Australia
The primary endpoint is the proportion of subjects achieving an IGA score of clear or almost clear at Week 12
Time frame: at Week 12
Proportion of subjects achieving a PASI-50
Time frame: at Week 12
Proportion of subjects achieving a PASI-75
Time frame: at Week 12
Proportion of subjects achieving a PASI-90
Time frame: at Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Local Institution
North Adelaide, South Australia, Australia
Local Institution
Carlton, Victoria, Australia
Local Institution
Malvern, Victoria, Australia
Local Institution
Calgary, Alberta, Canada
Local Institution
Edmonton, Alberta, Canada
Local Institution
Surrey, British Columbia, Canada
Local Institution
Winnipeg, Manitoba, Canada
Local Institution
St. John's, Newfoundland and Labrador, Canada
...and 11 more locations